Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Alexza Pharmaceuticals Inc announces launch of ADASUVE in Guatemala


Friday, 8 Aug 2014 09:00am EDT 

Alexza Pharmaceuticals Inc:Announced ADASUVE inhalation powder, pre-dispensed (loxapine) is available in Guatemala.Approval represents first ADASUVE approval in Latin America for Ferrer and Alexza.Ferrer is Alexza's commercial partner for ADASUVE in EU, Latin America and Commonwealth of Independent States countries.ADASUVE is first and only inhalation therapy for rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder.Ferrer is expected to launch ADASUVE in additional EU and Latin American countries in 2014 and 2015. 

Company Quote

1.17
-0.03 -2.50%
1:09pm EDT